Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00990223 · ClinicalTrials.gov registry record · Phase 1
Effects Of Eplerenone On Serum Aldesterone And Plasma Renin Activity
A Phase 1 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00990223 is a Phase 1 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 20 participants.
The verdict
NCT00990223, a Phase 1 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
To evaluate the changes in serum aldosterone and plasma renin activity on Day 0 and on Days 1 and 10 after administration of 100 mg of eplerenone daily for 10 days.
Interventions
- DRUG Eplerenone or Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2009-10 |
| Est. Completion | 2009-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00990223
The ClinicalTrials.gov registry entry for NCT00990223 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Eplerenone or Placebo is the first listed.
NCT00990223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00990223 about?
NCT00990223 is a clinical study titled "Effects Of Eplerenone On Serum Aldesterone And Plasma Renin Activity". To evaluate the changes in serum aldosterone and plasma renin activity on Day 0 and on Days 1 and 10 after administration of 100 mg of eplerenone daily for 10 days.
What is the current status of trial NCT00990223?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2009-10. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00990223?
The interventions under investigation include: Eplerenone or Placebo (DRUG).
Who is sponsoring clinical trial NCT00990223?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.